Vismodegib for Basal Cell Carcinoma

Vismodegib is an inhibitor of the hedgehog signaling pathway, a pathway involved in regulating adult stem cells that is over-active in more than 90% of basal cell carcinomas. This phase II clinical trial resulted in an increased progression free survival time for patients with metastatic basal cell carcinomas. I like this approach because it targets a specific stem cell pathway and also provides a new treatment opportunity for patients with metastatic basal cell carcinomas.
Roche Files Vismodegib for Basal Cell Carcinoma with FDA.


Speak Your Mind

*